Top

Published in:

01-01-2021 | Leflunomide | Expert Opinion

COVID-19 pandemic in Japan

Authors: Olga Amengual, Tatsuya Atsumi

Published in: Rheumatology International | Issue 1/2021

Abstract

The disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus Disease-2019 (COVID-19), is a global emergency. The first case of COVID-19 was confirmed in Japan in January 2020, a second outbreak of infection occurred in mid-March and a third peak at the beginning of August. The COVID-19 phenotype was milder in Japan than in other countries, although the restrictive measures applied in the country have not been as strict as in other places. Factors related to a possible reduced susceptibility to the pulmonary manifestations of SARS-CoV-2 may have contributed to better outcomes and lower mortality in Japan.

Sawalha AH, Manzi S (2020) Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol 7:S117–S120CrossRef

Kuroda M (2020) An epidemiological study of the SARS-CoV-2 genome in Japan. https://www.niid.gojp/niid/en/basic-science/467-genome/9598-genome-2020-1ehtml Accessed 27 October 2020

Ministry of Health, Labor, and Welfare About Coronavirus Disease 2019 (COVID-19). https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou_00006.html#1-1 Accessed 27 October 2020

Coronavirus resource center. COVID-19 Dashboard by the center for Systems Science and Engineering (CSSE) at Johns Hopkins University of Medicine. https://coronavirus.jhu.edu/map.html Accessed 27 October 2020

Coronavirus (COVID-19) deaths worldwide per one million population as of October 27, 2020, by country. https://www.statista.com/statistics/1104709/coronavirus-deaths-worldwide-per-million-inhabitants/ Accessed 27 October 2020

Iwasaki A, Grubaugh ND (2020) Why does Japan have so few cases of COVID-19? EMBO Mol Med 12:e12481CrossRef

D’Antiga L (2020) Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl 26:832–834CrossRef

Kondo Y, Kaneko Y, Oshige T, Fukui H, Saito S, Okayama M et al (2020) Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218157CrossRefPubMed

Yamada Z, Nanki T (2020) COVID-19 in a patient with rheumatoid arthritis during tocilizumab treatment. J Clin Rheumatol 26:240–241CrossRef

10.

Mokuda S, Tokunaga T, Masumoto J, Sugiyama E (2020) Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin 6 through STAT3 signaling in synovial tissues. J Rheumatol 47:1593–1595CrossRef

11.

Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N et al (2020) Care for patients with rheumatic diseases during COVID-19 pandemic: a position statement from APLAR. Int J Rheum Dis 23:717–722CrossRef

12.

Oku K, Atsumi T (2019) Rheumatology practice in Japan: challenges and opportunities. Rheumatol Int 39:1499–1505CrossRef

13.

Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68CrossRef

14.

Ito S, Sumida T (2004) Interstitial lung disease associated with leflunomide. Intern Med 43:1103–1104CrossRef

15.

Kamata Y, Nara H, Kamimura T, Haneda K, Iwamoto M, Masuyama J et al (2004) Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43:1201–1204CrossRef

16.

Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T et al (2009) Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48:1069–1072CrossRef

17.

Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY et al (2007) Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 56:2094–2096CrossRef

18.

Suissa S, Hudson M, Ernst P (2006) Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 54:1435–1439CrossRef

19.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280 e278CrossRef

20.

The Japanese Association for Infectious Diseases. Approach to drug treatment for COVID-19. https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_drug_200817.pdf Accessed 27 October 2020

21.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al (2020) Remdesivir for the treatment of Covid-19—Preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2007764CrossRefPubMedPubMedCentral

22.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 382:2327–2336CrossRef

23.

Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M et al (2020) A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01897-20CrossRefPubMedPubMedCentral

24.

Doi K, Ikeda M, Hayase N, Moriya K, Morimura N, the COVID-UTH study group (2020) Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19 a case series. Crit Care 24:392CrossRef

25.

Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T (2020) Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: report of three cases. J Infect Chemother 26:625–632CrossRef

Title: COVID-19 pandemic in Japan
Authors: Olga Amengual
Tatsuya Atsumi
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: Leflunomide
SARS-CoV-2
COVID-19
Published in: Rheumatology International / Issue 1/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04744-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

COVID-19 pandemic in Japan

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Altered expression of apoptosis-related, circulating cell-free miRNAs in children with familial Mediterranean fever: a cross-sectional study

Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic

Protracted febrile myalgia syndrome as the first manifestation of familial Mediterranean fever in children: case-based review

Statistical data presentation: a primer for rheumatology researchers

Analysis of a single-institution cohort of patients with Felty's syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis

Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page